Longtime OHS Canada columnist Alan Quilley dies after struggle with cancer April 26, 2021
OHS Canada, was the president of Safety Results, a consultancy and training service in Sherwood Park, Alta.
According to his obituary, occupational health and safety was a lifelong passion for Quilley. He authored several textbooks and delivered training courses to many future CRSPs over the course of his career.
A private ceremony will be held June 3 at Evergreen Memorial Gardens in Edmonton.
Advertisment
OHS Canada editor Marcel Vander Wier. “He will be greatly missed.”
“From the entire team at
OHS Canada, our condolences to his family and friends.”
Two Opdivo -based therapies are now authorized for first-line treatment of patients with advanced renal cell carcinoma in the European Union: Opdivo plus Yervoy in combination with Cabometyx Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo Cabometyx ® (cabozantinib) for the first-line treatment of adults with advanced renal cell carcinoma (RCC). The EC’s decision is based on results from the Phase 3 CheckMate -9ER trial, which demonstrated superior efficacy with Opdivo in combination with Cabometyx versus sunitinib across three key endpoints: progression-free survival (PFS), the primary endpoint, and objective response rate (ORR) and overall survival (OS). The combination of
5 неоспоримых преимуществ Tesla - Telegraf by telegraf.by - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from telegraf.by Daily Mail and Mail on Sunday newspapers.
Ocuphire Announces MIRA-2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary Endpoint forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.